Pf Prism Cv patents expiration
1. Bosulif patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6002008 | PF PRISM CV | Substituted 3-cyano quinolines |
Mar, 2018
(6 years ago) | |
| USRE42376 | PF PRISM CV | Substituted 3-cyanoquinolines |
Apr, 2024
(7 days ago) | |
| US7767678 | PF PRISM CV | Crystalline forms of 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methyl-1-piperazinyl)propoxy]-3-quinolinecarbonitrile and methods of preparing the same |
Nov, 2026
(2 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
USRE42376 (Pediatric) | PF PRISM CV | Substituted 3-cyanoquinolines |
Oct, 2024
(5 months from now) | |
| US7919625 | PF PRISM CV | 4-anilino-3-quinolinecarbonitriles for the treatment of chronic myelogenous leukemia (CML) |
Dec, 2025
(1 year, 7 months from now) | |
| US7417148 | PF PRISM CV | 4-anilino-3-quinolinecarbonitriles for the treatment of chronic myelogenous leukemia (CML) |
Dec, 2025
(1 year, 7 months from now) | |
|
US7417148 (Pediatric) | PF PRISM CV | 4-anilino-3-quinolinecarbonitriles for the treatment of chronic myelogenous leukemia (CML) |
Jun, 2026
(2 years from now) | |
|
US7919625 (Pediatric) | PF PRISM CV | 4-anilino-3-quinolinecarbonitriles for the treatment of chronic myelogenous leukemia (CML) |
Jun, 2026
(2 years from now) | |
|
US7767678 (Pediatric) | PF PRISM CV | Crystalline forms of 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methyl-1-piperazinyl)propoxy]-3-quinolinecarbonitrile and methods of preparing the same |
May, 2027
(3 years from now) | |
| US11103497 | PF PRISM CV | Treatment of imatinib resistant leukemia |
Feb, 2034
(9 years from now) | |
|
US11103497 (Pediatric) | PF PRISM CV | Treatment of imatinib resistant leukemia |
Aug, 2034
(10 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-163) | Dec 19, 2024 |
| Orphan Drug Exclusivity(ODE-444) | Sep 26, 2030 |
| New Indication(I-923) | Sep 26, 2026 |
| Pediatric Exclusivity(PED) | Mar 26, 2027 |
| New Indication(I-759) | Dec 19, 2020 |
| Orphan Drug Exclusivity(ODE) | Sep 04, 2019 |
| Orphan Drug Exclusivity(ODE-30) | Sep 04, 2019 |
| New Chemical Entity Exclusivity(NCE) | Sep 04, 2017 |
Drugs and Companies using BOSUTINIB MONOHYDRATE ingredient
NCE-1 date: 26 March, 2026
Market Authorisation Date: 04 September, 2012
Treatment: A method of treating patients with accelerated, or blast phase ph+ cml with resistance or intolerance to prior therapy; A method for treating a bcrabl positive leukemia in a subject that is resistant ...
Dosage: TABLET;ORAL; CAPSULE;ORAL
BOSULIF family patents
2. Chantix patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6410550 | PF PRISM CV | Aryl fused azapolycyclic compounds |
May, 2020
(3 years ago) | |
| US6890927 | PF PRISM CV | Tartrate salts of 5,8, 14-triazateracyclo[10.3.1.02,11 04.9]-hexadeca-2(11),3,5,7,9-pentaene and pharmaceutical compositions thereof |
May, 2022
(1 year, 11 months ago) | |
| US7265119 | PF PRISM CV | Tartrate salts of 5,8,14-triazatetracyclo[10.3.1.02,11.04.9]-hexadeca-2(11),3,5,7,9-pentaene and pharmaceutical compositions thereof |
Aug, 2022
(1 year, 8 months ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US6410550 (Pediatric) | PF PRISM CV | Aryl fused azapolycyclic compounds |
Nov, 2020
(3 years ago) | |
|
US6890927 (Pediatric) | PF PRISM CV | Tartrate salts of 5,8, 14-triazateracyclo[10.3.1.02,11 04.9]-hexadeca-2(11),3,5,7,9-pentaene and pharmaceutical compositions thereof |
Nov, 2022
(1 year, 5 months ago) | |
|
US7265119 (Pediatric) | PF PRISM CV | Tartrate salts of 5,8,14-triazatetracyclo[10.3.1.02,11.04.9]-hexadeca-2(11),3,5,7,9-pentaene and pharmaceutical compositions thereof |
Feb, 2023
(1 year, 2 months ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-192) | Dec 16, 2019 |
| Pediatric Exclusivity(PED) | Aug 22, 2022 |
| M(M-183) | Aug 12, 2019 |
| M(M-144) | Oct 15, 2017 |
| M(M-143) | Oct 15, 2017 |
| M(M-237) | Feb 22, 2022 |
| M(M-105) | Jul 22, 2014 |
Drugs and Companies using VARENICLINE TARTRATE ingredient
Market Authorisation Date: 10 May, 2006
Treatment: Aid to smoking cessation
Dosage: TABLET;ORAL
CHANTIX family patents
3. Inlyta patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6534524 | PF PRISM CV | Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use |
Apr, 2025
(1 year, 8 days from now) | |
| US8791140 | PF PRISM CV | Crystalline forms of 6-[2-(methylcarbamoyl)phenylsulfanyl]-3-E-[2-(pyridin-2-yl)ethenyondazole suitable for the treatment of abnormal cell growth in mammals |
Dec, 2030
(6 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7141581 | PF PRISM CV | Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use |
Jun, 2020
(3 years ago) | |
| US10570202 | PF PRISM CV | Combination of a PD-1 antagonist and a VEGFR inhibitor for treating cancer |
Feb, 2035
(10 years from now) | |
| US10869924 | PF PRISM CV | PD-L1 antagonist combination treatments |
Jan, 2037
(12 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jan 27, 2017 |
Drugs and Companies using AXITINIB ingredient
NCE-1 date: 28 January, 2016
Market Authorisation Date: 27 January, 2012
Treatment: Treatment of renal cell carcinoma; In combination with pembrolizumab for the first-line treatment of patients with advanced renal cell carcinoma; Axitinib in combination with avelumab for the first-li...
Dosage: TABLET;ORAL
INLYTA family patents
4. Pristiq patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6673838 | PF PRISM CV | Succinate salt of O-desmethyl-venlafaxine |
Mar, 2022
(2 years ago) | |
| US8269040 | PF PRISM CV | Derivatives of venlafaxine and methods of preparing and using the same |
Jul, 2027
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-675) | Feb 14, 2016 |
| M(M-222) | Feb 06, 2021 |
| New Chemical Entity Exclusivity(NCE) | Mar 01, 2013 |
Drugs and Companies using DESVENLAFAXINE SUCCINATE ingredient
NCE-1 date: 01 March, 2012
Market Authorisation Date: 20 August, 2014
Treatment: Maintenance treatment of major depressive disorder (mdd)
Dosage: TABLET, EXTENDED RELEASE;ORAL
PRISTIQ family patents
5. Rapamune patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US5403833 (Pediatric) | PF PRISM CV | Methods of inhibiting transplant rejecton in mammals using rapamycin and derivatives and prodrugs thereof |
Oct, 2012
(11 years ago) | |
| US5100899 | PF PRISM CV | Methods of inhibiting transplant rejection in mammals using rapamycin and derivatives and prodrugs thereof |
Jul, 2013
(10 years ago) | |
| US5536729 | PF PRISM CV | Rapamycin formulations for oral administration |
Sep, 2013
(10 years ago) | |
|
US5100899 (Pediatric) | PF PRISM CV | Methods of inhibiting transplant rejection in mammals using rapamycin and derivatives and prodrugs thereof |
Jan, 2014
(10 years ago) | |
|
US5536729 (Pediatric) | PF PRISM CV | Rapamycin formulations for oral administration |
Mar, 2014
(10 years ago) | |
| US5989591 | PF PRISM CV | Rapamycin formulations for oral administration |
Mar, 2018
(6 years ago) | |
|
US5989591 (Pediatric) | PF PRISM CV | Rapamycin formulations for oral administration |
Sep, 2018
(5 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE) | May 28, 2022 |
| Orphan Drug Exclusivity(ODE-92) | May 28, 2022 |
Drugs and Companies using SIROLIMUS ingredient
Market Authorisation Date: 25 January, 2010
Treatment: Inhibiting transplant rejection using rapamycin (sirolimus)
Dosage: TABLET;ORAL; SOLUTION;ORAL
RAPAMUNE family patents
6. Torisel patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US5362718 | PF PRISM CV | Rapamycin hydroxyesters |
Feb, 2019
(5 years ago) | |
| USRE44768 | PF PRISM CV | Rapamycin hydroxyesters |
Feb, 2019
(5 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US5362718 (Pediatric) | PF PRISM CV | Rapamycin hydroxyesters |
Aug, 2019
(4 years ago) | |
|
USRE44768 (Pediatric) | PF PRISM CV | Rapamycin hydroxyesters |
Aug, 2019
(4 years ago) | |
| US8722700 | PF PRISM CV | CCI-779 formulations for parenteral administration |
Jul, 2023
(8 months ago) | |
| US8455539 | PF PRISM CV | CCI-779 concentrate formulations |
Jul, 2023
(8 months ago) | |
| US8299116 | PF PRISM CV | CCI-779 concentrate formulations |
Jul, 2023
(8 months ago) | |
|
US8299116 (Pediatric) | PF PRISM CV | CCI-779 concentrate formulations |
Jan, 2024
(2 months ago) | |
|
US8455539 (Pediatric) | PF PRISM CV | CCI-779 concentrate formulations |
Jan, 2024
(2 months ago) | |
|
US8722700 (Pediatric) | PF PRISM CV | CCI-779 formulations for parenteral administration |
Jan, 2024
(2 months ago) | |
| US8026276 | PF PRISM CV | Parenteral CCI-779 formulations containing cosolvents, an antioxidant, and a surfactant |
Jan, 2026
(1 year, 8 months from now) | |
|
US8026276 (Pediatric) | PF PRISM CV | Parenteral CCI-779 formulations containing cosolvents, an antioxidant, and a surfactant |
Jul, 2026
(2 years from now) | |
| US8791097 | PF PRISM CV | Anti-tumor activity of CCI-779 in papillary renal cell cancer |
May, 2032
(8 years from now) | |
|
US8791097 (Pediatric) | PF PRISM CV | Anti-tumor activity of CCI-779 in papillary renal cell cancer |
Nov, 2032
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-61) | May 30, 2015 |
| M(M-92) | Jul 09, 2013 |
| Orphan Drug Exclusivity(ODE) | May 30, 2014 |
| M(M-91) | Apr 26, 2013 |
| Pediatric Exclusivity(PED) | Jan 09, 2014 |
Drugs and Companies using TEMSIROLIMUS ingredient
Market Authorisation Date: 30 May, 2007
Treatment: Method of treating metastatic papillary renal cell carcinoma with temsirolimus.
Dosage: SOLUTION;INTRAVENOUS
TORISEL family patents
7. Tygacil patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| USRE40183 | PF PRISM CV | 7-Substituted-9-substituted amino-6-demethyl-6-deoxytetracyclines |
Apr, 2016
(8 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| USRE40086 | PF PRISM CV | Method for treating bacterial infection with novel 7-substituted-9-substituted amino 6-demethyl-6-deoxytetracyclines |
Jun, 2013
(10 years ago) | |
| US9694078 | PF PRISM CV | Tigecycline compositions and methods of preparation |
Mar, 2026
(1 year, 10 months from now) | |
| US10588975 | PF PRISM CV | Tigecycline compositions and methods of preparation |
Mar, 2026
(1 year, 10 months from now) | |
| US9254328 | PF PRISM CV | Tigecycline compositions and methods of preparation |
Mar, 2026
(1 year, 10 months from now) | |
| US8975242 | PF PRISM CV | Tigecycline compositions and methods of preparation |
Oct, 2028
(4 years from now) | |
| US7879828 | PF PRISM CV | Tigecycline compositions and methods of preparation |
Feb, 2029
(4 years from now) | |
| US8372995 | PF PRISM CV | Crystalline solid forms of tigecycline and methods of preparing same |
Oct, 2030
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-587) | Mar 20, 2012 |
| New Indication(I-588) | Mar 20, 2012 |
| New Indication(I-586) | Mar 20, 2012 |
Drugs and Companies using TIGECYCLINE ingredient
Market Authorisation Date: 15 June, 2005
Treatment: Method of treating bacterial infections
Dosage: POWDER;INTRAVENOUS
TYGACIL family patents
8. Vfend patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US5567817 | PF PRISM CV | Triazole antifungal agents |
May, 2016
(7 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6632803 | PF PRISM CV | Pharmaceutical formulations containing voriconazole |
Jun, 2018
(5 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | Jan 29, 2022 |
Drugs and Companies using VORICONAZOLE ingredient
Market Authorisation Date: 24 May, 2002
Treatment: Treatment of fungal infections
Dosage: TABLET;ORAL; INJECTABLE;INTRAVENOUS; FOR SUSPENSION;ORAL
VFEND family patents
9. Xalkori patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8785632 | PF PRISM CV | Enantiomerically pure aminoheteroaryl compounds as protein kinase inhibitors |
Mar, 2025
(10 months from now) | |
| US7230098 | PF PRISM CV | Aminoheteroaryl compounds as protein kinase inhibitors |
Aug, 2025
(1 year, 4 months from now) | |
| US7858643 | PF PRISM CV | Enantiomerically pure aminoheteroaryl compounds as protein kinase inhibitors |
Oct, 2029
(5 years from now) | |
| US8217057 | PF PRISM CV | Polymorphs of a c-MET/HGFR inhibitor |
Nov, 2029
(5 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7825137 | PF PRISM CV | Method of treating abnormal cell growth |
May, 2027
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-852) | Jan 14, 2024 |
| New Indication(I-897) | Jul 14, 2025 |
Drugs and Companies using CRIZOTINIB ingredient
Market Authorisation Date: 07 September, 2023
Treatment: Treatment of patients with metastatic non-small cell lung cancer (nsclc) that is anaplastic lymphoma kinase (alk)-positive
Dosage: CAPSULE, PELLETS;ORAL; CAPSULE;ORAL
XALKORI family patents
10. Xeljanz patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7301023 | PF PRISM CV | Chiral salt resolution |
Dec, 2020
(3 years ago) | |
| US7265221 | PF PRISM CV | Pyrrolo[2,3-d]pyrimidine compounds |
Dec, 2020
(3 years ago) | |
| US6965027 | PF PRISM CV | Crystalline 3-{4-methyl-3-[methyl-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amino]-piperidin-1-yl}-3-oxo-propionitrile citrate |
Mar, 2023
(1 year, 27 days ago) | |
| USRE41783 | PF PRISM CV | Pyrrolo[2,3-D]pyrimidine compounds |
Dec, 2025
(1 year, 7 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7091208 | PF PRISM CV | Pyrrolo[2,3-D]pyrimidine compounds |
Dec, 2020
(3 years ago) | |
| US7842699 | PF PRISM CV | Pyrrolo[2,3-D]pyrimidine compounds |
Dec, 2020
(3 years ago) | |
| US6956041 | PF PRISM CV | Pyrrolo[2,3-d]pyrimidine compounds |
Dec, 2020
(3 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-879) | Dec 14, 2024 |
| New Patient Population(NPP) | Sep 25, 2023 |
| New Indication(I-761) | Dec 14, 2020 |
| M(M-135) | Feb 21, 2017 |
| New Indication(I-780) | May 30, 2021 |
| New Chemical Entity Exclusivity(NCE) | Nov 06, 2017 |
Drugs and Companies using TOFACITINIB CITRATE ingredient
NCE-1 date: 06 November, 2016
Market Authorisation Date: 06 November, 2012
Treatment: Treatment of rheumatoid arthritis; Treatment of adult patients with moderately to severely active ulcerative colitis (uc)
Dosage: TABLET;ORAL
XELJANZ family patents
11. Zmax patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6268489 | PF PRISM CV | Azithromycin dihydrate |
Jul, 2018
(5 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6068859 | PF PRISM CV | Controlled-release dosage forms of Azithromycin |
May, 2017
(6 years ago) | |
| US6984403 | PF PRISM CV | Azithromycin dosage forms with reduced side effects |
Feb, 2024
(2 months ago) | |
| US7887844 | PF PRISM CV | Multiparticulate crystalline drug compositions having controlled release profiles |
Feb, 2024
(2 months ago) | |
Drugs and Companies using AZITHROMYCIN ingredient
Market Authorisation Date: 10 June, 2005
Treatment: Method of treating bacterial infections
Dosage: FOR SUSPENSION, EXTENDED RELEASE;ORAL
ZMAX family patents